NASH is associated with numerous risk factors, such as obesity and type 2 diabetes mellitus (T2DM) (Rivera, 2008).The clinical trials with OCA have proven FXR as a target for the treatment of fatty liver disorders (Mudaliar et al., 2013; Neuschwander-Tetri et al., 2015). Here, NR1H4 is linked to type 2 diabetes mellitus.